Newcastle Disease Virus at the Forefront of Cancer Immunotherapy

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Newcastle disease virus (NDV) exhibits oncolytic properties and stimulates antitumor immune responses, with a history of research since the 1950s.
• NDV selectively targets and lyses cancer cells by exploiting their defective antiviral defenses, leading to inflammation and immune cell recruitment within the tumor microenvironment.

Purpose of the Study:

• To evaluate the oncolytic and immunomodulatory effects of Newcastle disease virus (NDV) in preclinical and clinical settings.
• To investigate the potential of NDV in combination with immune checkpoint blockade for enhanced cancer therapy.

Main Methods:

• Preclinical studies in animal models involving intratumoral injection of NDV.
• Administration of naturally occurring NDV intravenously in clinical trials.
• Combination therapy of intratumoral NDV with systemic immune checkpoint blockade, including studies with genetically modified NDV.

Main Results:

• NDV demonstrated selective cancer cell lysis and induction of antitumor immune responses, including T cell infiltration into local and distant tumors.
• Combination therapy with NDV and immune checkpoint blockade led to significant tumor regression, both locally and systemically.
• Clinical trials showed durable responses across multiple cancer types following intravenous NDV administration.

Conclusions:

• NDV is a promising oncolytic virus with potent antitumor immune-stimulating capabilities.
• Combination strategies involving NDV and immune checkpoint inhibitors warrant further clinical investigation for various cancers.
• Recombinant NDV and combination therapies are advancing to clinical trials for improved cancer treatment outcomes.